Serum M3/M21 in ovarian cancer patients
1997

Evaluating M3/M21 as a Tumor Marker in Ovarian Cancer

Sample size: 75 publication Evidence: moderate

Author Information

Author(s): C Tempfer, L Hefler, G Haeusler, G Sliutz, E Hanzal, A Reinthaller, CH Kainz

Primary Institution: University of Vienna, Medical School

Hypothesis

The study aims to evaluate the clinical usefulness of the serum evaluation of M3/M21 in patients with ovarian cancer.

Conclusion

M3/M21 serum levels are elevated in ovarian cancer patients and may be useful for monitoring and predicting outcomes.

Supporting Evidence

  • M3/M21 showed a sensitivity of 78% and specificity of 85%.
  • Elevated M3/M21 serum levels before therapy were associated with poor overall survival.
  • Lead time effects were observed in 19 patients, ranging from 2 to 8 months.

Takeaway

Doctors looked at a blood test called M3/M21 to see if it can help find ovarian cancer early and predict how well patients will do.

Methodology

This retrospective study included serological examinations of 75 patients with ovarian cancer, evaluating M3/M21 serum levels before surgery and during follow-up.

Potential Biases

Potential bias due to the retrospective nature and the specific patient population studied.

Limitations

The study is retrospective and may not account for all variables affecting outcomes.

Participant Demographics

Median age was 55.6 years, with patients across FIGO stages Ia to III.

Statistical Information

P-Value

0.02

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication